Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of tougher times ahead.

The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling medicines to go off patent in the coming weeks.

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in demand for the company’s blockbuster psoriasis treatment.

Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data centers in the U.S.

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee

What Hartford Funds and Ned Davis Research found was that income stocks more than doubled the average annual return of non-payers -- 9.17% versus 4.27% -- and did so while being less volatile than the benchmark S&P 500. However, high-quality dividend stocks don't grow on trees and require some effort by investors to uncover.

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside

House Speaker Mike Johnson revealed President Biden insisted to him he hadn’t issued an executive order freezing liquid natural gas export permits — despite doing so less than a month

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share.

The Wall Street Journal editorial board tore into President Donald Trump for pardoning the rioters who attacked the Capitol on Jan. 6, 2021.

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Investors love dividend stocks, especially the blue-chip variety,